Information Library
News Items
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by:
- Most Recent
- Title
-
QUINTILES EXTENDS PHASE I CAPACITY AND CAPABILITIES
March 8, 2010 – Quintiles announced the opening of its expanded research facility in London, UK, increasing its Phase I capacity and extending its ability to drive progress in translational medicine.
-
QUINTILES SPEEDS PATIENT RECRUITMENT WITH LOCAL MARKETING AUTOMATION TECHNOLOGY
Quintiles today launched innovative, web-based technology to enable world-class marketing for clinical trial enrollment at an individual site-level. Named Quintiles Trial Enrollment Accelerator (QTEA), this new solution will speed patient recruitment by helping customers better manage the quality, consistency and effectiveness of messaging and media outreach.
-
QUINTILES ADDS TISSUE TESTING SERVICES IN CHINA
February 16, 2010 - Quintiles today announced the availability of anatomic pathology services through its central laboratory in Beijing, China, to help biopharmaceutical companies develop more effective cancer treatments.
-
Quintiles Again Named to Training Top 125, for Workforce Training and Development Excellence
Quintiles has again been named to Training magazine’s “Training Top 125,” the publication’s annual report that ranks companies based on their employer-sponsored training and development programs.
-
QUINTILES AND MOVETIS ANNOUNCE STRATEGIC ALLIANCE
January 28, 2010 - Quintiles announced a strategic alliance with Movetis NV for commercialization of its new product, Resolor (prucalopride), in the U.K. and Germany.
-
QUINTILES ANNOUNCES NEW POSITIONING, NEW BRAND IDENTITY
January 25, 2010 – Quintiles, the world’s leading biopharmaceutical services company, has launched a new positioning and brand identity, driven by the company’s growing ability to solve customers’ emerging clinical and commercial challenges.
-
QUINTILES EXECUTIVE ELECTED CHAIR-ELECT OF CDISC
January 19, 2010 – Quintiles announced that Paula Brown Stafford, Executive Vice President, Integrated Clinical Services, has been elected chair-elect of the Board of Directors of CDISC, a global organization that leads the development of standards to reduce complexity in biomedical research to speed new therapies to market and improve the flow of research information to healthcare.
-
QUINTILES SELECTS INVIVODATA AS PRIMARY PARTNER FOR ePRO SOLUTIONS
January 18, 2010 — Quintiles, the world’s leading biopharmaceutical services company, and invivodata, inc., an industry leader in patient reported outcomes (PRO) solutions and services for global clinical research, announced a collaboration agreement to transform the way Patient Reported Outcomes (PRO) are used in clinical research to speed drug development.
-
QUINTILES’ SUCCESS IN MANAGING STRATEGIC ALLIANCES PROFILED IN HARVARD BUSINESS REVIEW
January 11, 2010 - “Managing Alliances with the Balanced Scorecard” details how Solvay Pharmaceuticals and Quintiles managed their innovative development alliance to deliver value for both companies. Article appeared in special double issue (January-February 2010) of Harvard Business Review.
-
QUINTILES VIRTUAL CLINICAL RESEARCH COMMUNITY REACHES 2 MILLION
December 22, 2009 – Quintiles announced it has developed a community of more than 2 million clinically profiled patients who have opted in to volunteer or provide insights and guidance to advance clinical research through its proprietary Web site iGuard.org.
